The Phase I trial — meaning it is the first in humans and had the goal of showing the therapy is safe — examined 12 patients with gastrointestinal cancers, including colon and rectal cancer.

In the recent RAPIDO randomized phase III trial, TNT with 5 × 5 Gy followed by consolidation chemotherapy and TME ... we suggest that early response assessment in neoadjuvant rectal cancer trials, on ...

The study evaluates the feasibility, safety, and tolerability of neoadjuvant radiotherapy followed by a CDK4/6 inhibitor (dalpiciclib) and hormonal therapy in treatment-naive patients with unilateral ...

The objectives are as follows: To assess the effectiveness and safety of total neoadjuvant therapy versus standard therapy in individuals with locally advanced rectal cancer. This is a protocol. Was ...

German Cancer Consortium German Cancer Research Center, Heidelberg, Germany iDepartment of Radiation Oncology, Cyberknife and Radiation Therapy, University of Cologne, Faculty of Medicine and ...

neoadjuvant therapy in breast cancer, total neoadjuvant therapy in rectal cancer, and the use of biomarkers to inform immunotherapy treatment decisions in advanced cancers. 2. Biopharma ...

(IN BRIEF) The POTOMAC Phase III trial results show that adding Imfinzi to standard BCG induction and maintenance therapy improves disease-free survival (DFS) for patients with high-risk ...

In early-stage estrogen receptor-positive (ER + ) breast cancer, resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i) often involve a shift away from estrogen-driven proliferation. The ...

neoadjuvant therapy in breast cancer, total neoadjuvant therapy in rectal cancer, and the use of biomarkers to inform immunotherapy treatment decisions in advanced cancers. 2. Biopharma Collaborations ...

A recent study reported that patients with residual urothelial carcinoma of the bladder subsequent to neoadjuvant/induction chemotherapy (NAIC ... pN1-3). Of the total cohort, 175 (34.1%) patients ...

Because we observed variable responses in individual mice to losartan+anti-PD1 therapy, we sought to identify predictive biomarkers informed by the GBM immune compartment prior to therapy. Building on ...

The treatment for her cancer is divided into different phases: induction, consolidation, intensification, maintenance. Over the past six months, she has gone through the induction and consolidation ...